Methods of using 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine compounds

A method for the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder associated with SSAO inhibition, which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I),

• or a pharmaceutically acceptable salt, geometrical isomer, tautomer, optical isomer or N-oxide thereof, wherein:
• R1 is selected from:
• (a) hydrogen,
• (b) C1-6-alkyl, and
• (c) —NR4AR4B;
• R2 is selected from:
• (a) hydrogen,
• (b) C1-6-alkyl,
• (c) halo-C1-6-alkyl,
• (d) hydroxy-C1-6-alkyl,
• (e) C1-6-alkoxy-C1-6-alkyl,
• (f) halo-C1-6-alkoxy-C1-6-alkyl,
• (g) N(R4AR4B)—C1-6-alkyl,
• (h) —C(O)NR4AR4B, and
• (i) —C(O)O—C1-6-alkyl;
• R3 is selected from:
• (a) C1-6-alkyl,
• (b) halo-C1-6-alkyl,
• (c) hydroxy-C1-6-alkyl,
• (d) C1-6-alkoxy-C1-6-alkyl,
• (e) halo-C1-6-alkoxy-C1-6-alkyl,
• (f) N(R4AR4B)—C1-6-alkyl,
• (g) C6-10-aryl-C1-4-alkyl,
• (h) heteroaryl-C1-4-alkyl,
• (i) C6-10-aryloxy-C1-4-alkyl,
• (j) heteroaryloxy-C1-4-alkyl,
• (k) C3-8-cycloalkyl,
• (l) C3-8-cycloalkyl-C1-4-alkyl,
• (m) heterocyclyl, and
• (n) heterocyclyl-C1-4-alkyl,
• wherein any aryl or heteroaryl residue is optionally substituted with one more substituents independently selected from halogen, hydroxy, cyano, nitro, CF3, C1-4-alkyl, C1-4-alkoxy and —NR4AR4B, and wherein any cycloalkyl or heterocyclyl residue is optionally substituted with one or more substituents independently selected from halogen, hydroxy, C1-4-alkyl, C1-4-alkoxy and —NR4AR4B;
• R4A and R4B are each independently selected from:
• (a) hydrogen,
• (b) C1-6-alkyl, and
• (c) C1-6-acyl.